Nivolumab and Ipilimumab Show Promise for Relapsed Melanoma

A new study presented at the ESMO Sarcoma and Rare Cancers Congress 2026 suggests that a combination of nivolumab and ipilimumab, followed by surgery, may be an effective treatment strategy for patients with locoregional relapse of melanoma after initial adjuvant therapy. This approach offers hope for a patient population where treatment options are limited and outcomes are often challenging.

Understanding the Challenge of Relapsed Melanoma

Melanoma, a serious form of skin cancer, is increasingly treated with immune checkpoint inhibitors and targeted therapies. However, the optimal management of patients who experience locoregional relapse – when the cancer returns in or near the original site – after or during adjuvant therapy (treatment given after surgery to prevent recurrence) remains unclear. Effective treatment options in this setting are not well-defined, highlighting the need for new strategies.

Study Design and Findings

Researchers conducted a retrospective study at a single center, focusing on 12 patients with stage III melanoma who had previously undergone surgery and received adjuvant therapy. These patients subsequently developed locoregional relapse and were treated with induction immunotherapy using nivolumab plus ipilimumab, followed by curative-intent surgical resection.

The study revealed encouraging results:

• The median age of patients was 57 years, with 33% being female.
• Half of the patients had BRAFV600-mutated melanoma and received BRAF/MEK inhibitor therapy as adjuvant treatment, although the other half had BRAF wild-type disease and received anti–PD-1 therapy.
• Six patients relapsed during adjuvant therapy, while the remaining six relapsed after completing it, with a median time to progression of 14.9 months.
• The median time between starting nivolumab plus ipilimumab and undergoing surgery was 2.1 months.
• Four patients achieved a complete or major pathological response.
• At three years after starting combination immunotherapy, the progression-free survival rate was 55% and the overall survival rate was 92%.
• Notably, patients who achieved a major pathological response did not experience relapse or death during follow-up.
• Outcomes were consistent regardless of BRAF mutation status.

The Importance of Surgical Evaluation

Interestingly, the study found no correlation between radiological response (how the tumor appears on imaging scans) and pathological response (what is observed during surgery and examination of tissue). This suggests that surgical evaluation remains crucial, even when imaging doesn’t show a strong response. This underscores the importance of a multidisciplinary approach to managing these complex cases.

Clinical Implications and Future Directions

These findings suggest that nivolumab plus ipilimumab followed by surgery may be a valuable salvage strategy for patients with locoregional melanoma relapse after adjuvant therapy, irrespective of prior treatment or BRAF mutation status. The combination therapy appears to offer a significant benefit in terms of progression-free and overall survival.

Further research is needed to confirm these findings in larger, prospective studies. Identifying biomarkers that can predict response to treatment will also be crucial for personalizing therapy and optimizing outcomes for patients with relapsed melanoma.